A comparison of the effects of quetiapine ('Seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment

International Clinical Psychopharmacology

Volumn 15, Issue 3, 2000, Pages 121-131

  Emsley, R A ^a   Raniwalla, J ^b   Bailey, P J ^b   Jones, A M ^b  

^a UNIVERSITY OF STELLENBOSCH   (South Africa)

^b ASTRAZENECA   (United Kingdom)

Author keywords

Partial response; Quetiapine; Schizophrenia

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; PROLACTIN; QUETIAPINE;

ADULT; AGED; AKATHISIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE HYPERTONIA; ORTHOSTATIC HYPOTENSION; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SOMNOLENCE; VERTIGO; XEROSTOMIA;

EID: 0034075361     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200015030-00001     Document Type: Article

References (29)

1. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association.
2. Arvanitis LA, Miller BG, and the Seroquel Trial 13 study group (1997) Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42:233-246.
3. Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P (1998) Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry 155:499-504.
4. Borison RL, Arvanitis LA, Miller BG, and the 'Seroquel' Study Group (1996) ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 16:158-169.
5. Breier A, Buchanan RW, Kirkpatrick B (1994) Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry 151:2-26.
6. Breier A, Hamilton SH (1999) Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia. Biol Psychiatry 45:403-411.
7. Chincilla A, Vega M, Cebollada A, Ruiz R (1997) A long-term treatment with 'Seroquel' (quetiapine) in a severe schizophrenia patient. Eur Neuropsychopharmacol 7 (Suppl. 2):S198-S199.
8. Conley RR, Buchanan RW (1997) Evaluation of treatment resistant schizophrenia. Schizophr Bull 23:663-674.
9. Conley RR, Kelly DL, Gale EA (1998) Olanzapine response in treatment-refractory schizophrenic patients with a history of substance abuse. Schizophr Res 33:95-101.
10. Conley RR, Tamminga CA, Kelly DL, Richardson CM (1999) Treatment-resistant schizophrenic patients respond to clozapine after olanzapine non-response. Biol Psychiatry 46:73-77.
11. Copolov DL, Link CGG, Kowalcyk B (2000) A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, 'Seroquel') and haloperidol in schizophrenia. Psychol Med 30:95-106.
12. Flynn SW, MacEwan GW, Altman S, Kopala LC, Fredrikson DH, Smith GN, Honer WG (1998) An open comparison of clozapine and risperidone in treatment-resistant schizophrenia. Pharmacopsychiatry 31:25-29.
13. Ghadirian AM, Chouinard G, Annable L (1992) Sexual dysfunction and plasma prolactin levels in neuroleptictreated schizophrenic outpatients. J Nerv Ment Dis 170:463-467.
14. Goldman HH, Manderscheid RW (1987) Epidemiology of chronic mental disorder. In: The Chronic Mental Patient /II (Menninger WW, Hannah GT, eds.), Washington, DC: American Psychiatric Press.
15. Guy W, Bonato R (1970) Manual for the ECDEU Assessment Battery R, 2nd revised edn. Chevy Chase, MD: National Institute of Mental Health.
16. Hamner MB, Goldstein JM, Arvanitis LA, Borison RL (1998) Quetiapine and prolactin: low incidence of side effects referable to hyperprolactinemia is consistent with quetiapine's minimal effects on plasma prolactin. American Society of Clinical Psychopharmacology Meeting, San Juan, Puerto Rico [abstract].
17. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
18. Katz SE (1987) Hospitalisation and the mental health service system. In: Comprehensive Textbook of Psychiatry, 5th edn, Vol. 2 (Kaplan HI, Sadock BJ, eds.), Baltimore: Williams and Wilkins, pp. 2083-2089.
19. Kay S, Fiszbein A, Opler L (1987) The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
20. Meats P (1997) Quetiapine ('Seroquel'); an effective and well-tolerated atypical antipsychotic. Int J Psychiatr Clin Pract 1:231-239.
21. Overall JE, Gorham DR (1962) The brief psychiatric rating scale. Psychiatr Reports 10:799-812.
22. Peuskens J, Link CGG (1997) A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand 96:265-273.
23. Rak IW, Jones AM, Raniwalla J, Phung D, Melvin K (2000) Weight changes in patients treated with Seroquel (quetiapine). Schizophrenia Res (in press).
24. Rosenstein MJ, Milazzo-Sayre LJ, Manderscheid RW (1989) Care of persons with schizophrenia: a statistical profile. Schizophr Bull 15:45-58.
25. Saller CF, Salama AI (1993) Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology 112:285-292.
26. Simpson GM, Angus JWS (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand 212:11-19.
27. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CGG, and the Seroquel Study Group (1997) Quetiapine in patients with schizophrenia: a high-and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 54:549-557.
28. Sullivan G, Lukoff D (1990) Sexual side-effects of antipsychotic medication: evaluation and interventions. Hosp Commun Psychiatry 11:238-241.
29. Tollefson GD, Beasley CMJ, Tran PV, Street JS, Krueger JA, Tamura RN, et al. (1997) Olanzapine vs. haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154:457-465.